Targeted cancer therapies part 1 #276.
作者信息
Gharwan Helen, Groninger Hunter
出版信息
J Palliat Med. 2014 Feb;17(2):236-40. doi: 10.1089/jpm.2013.9452. Epub 2014 Jan 17.
Abstract
摘要
相似文献
1
Targeted cancer therapies part 1 #276.
J Palliat Med. 2014 Feb;17(2):236-40. doi: 10.1089/jpm.2013.9452. Epub 2014 Jan 17.
2
Targeted anti-cancer therapy in the elderly.
Crit Rev Oncol Hematol. 2011 Jun;78(3):227-42. doi: 10.1016/j.critrevonc.2010.06.001. Epub 2010 Jul 5.
3
Cardiovascular Toxic Effects of Targeted Cancer Therapies.
N Engl J Med. 2016 Oct 13;375(15):1457-1467. doi: 10.1056/NEJMra1100265.
4
My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.
Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11579-11586. doi: 10.1073/pnas.1816012116. Epub 2019 May 10.
5
Targeting ALK, ROS1, and BRAF kinases.
J Thorac Oncol. 2012 Dec;7(16 Suppl 5):S375-6. doi: 10.1097/JTO.0b013e31826df05e.
6
Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
J Drug Target. 2016;24(3):192-211. doi: 10.3109/1061186X.2015.1068319. Epub 2015 Jul 27.
7
Anti-EGFR therapy update: clinical experience and adverse event insights.
Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):3-4.
8
[Protein tyrosine kinase inhibitors in cancer therapy].
Pathol Biol (Paris). 2012 Aug;60(4):229-33. doi: 10.1016/j.patbio.2012.05.007. Epub 2012 Jun 26.
9
The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics.
Anticancer Agents Med Chem. 2015;15(7):869-80. doi: 10.2174/1871520615666150318101845.
10
Foreword. Target therapy for cancer: anti-cancer drugs targeting growth-factor signaling molecules.
Biol Pharm Bull. 2011;34(12):1773. doi: 10.1248/bpb.34.1773.
本文引用的文献
1
Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.
Drug Saf. 2013 Jun;36(6):413-26. doi: 10.1007/s40264-013-0050-x.
2
Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).
Drug Saf. 2013 May;36(5):295-316. doi: 10.1007/s40264-013-0047-5.
3
Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.
Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S19-27. doi: 10.1007/s10555-012-9355-y.
4
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
J Clin Oncol. 2011 Jun 20;29(18):2543-9. doi: 10.1200/JCO.2011.35.2393. Epub 2011 May 23.
5
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Oncology. 2009;77(5):257-71. doi: 10.1159/000258880. Epub 2009 Nov 16.
6
Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.
Drug Des Devel Ther. 2009 Feb 6;2:215-9. doi: 10.2147/dddt.s3843.
7
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
Curr Drug Metab. 2009 Jun;10(5):470-81. doi: 10.2174/138920009788897975.
8
Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Acc Chem Res. 2008 Jan;41(1):98-107. doi: 10.1021/ar700108g. Epub 2007 Aug 18.
9
Tyrosine kinases as targets for cancer therapy.
N Engl J Med. 2005 Jul 14;353(2):172-87. doi: 10.1056/NEJMra044389.
Zotero 插件